Search

Displaying results 4901 - 4910 of 9333 in total
  1. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    and adenocarcinoma of the cervix) … CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  2. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

  3. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape. … Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.

  4. Drug

    Cositecan

    go.drugbank.com/drugs/DB05806
    Investigational

    Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.

  5. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    Cobitolimod

    go.drugbank.com/drugs/DB14819
    Investigational

    Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).

  8. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  9. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  10. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    This drug is a dissociative anesthetic agent that falls under the drug category of _NMDA receptor antagonists_. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. … Tiletamine hydrochloride, the salt form, exists as odorless white crystals.